

Michael Warren Peterson, D.O., F.A.A.D.

CCT Research
1910 S Stapley Drive, Suite 120
Mesa, AZ 85204

CONTACT INFORMATION:

Site Selection and Information:

Bobbie Theodore, VP Sponsor Relations/BD
Apex Innovative Sciences, Alliance Division
Tel. 916-803-7149 (cell)
Email: bobbietheodore@apexsci.com

AFFILIATIONS:

South Ogden Family Medicine Ogden Clinic/CCT Research
5740 Crestwood Drive
Ogden, Utah 84405

Olympus Family Medicine/CCT Research
4624 Holladay Boulevard
Holladay, Utah 84117

Springville Dermatology/CCT Research
732 N. Main St.
Springville, Utah 84663

EDUCATION:

2000 Doctor of Osteopathy
College of Osteopathic Medicine of the Pacific, Pomona, CA

1996 B.A. in Chinese
Brigham Young University, Provo, UT

LICENSURE:

Utah — Physician - License Number: 7247463-1204
Utah — Physician CS — License Number: 7247463-8904

RESIDENCY:

2011-2012 Dermatopathology Fellowship
University of Texas Southwestern Medical Center, Dallas, TX

2004-2007 Dermatology
Medical College of Wisconsin Dermatology Department, Milwaukee, WI

4/27/2021

CERTIFICATION:

American Board of Dermatology — Certified
American Board of Dermatopathology — Certified

MEMBERSHIPS:

2012 – Present	Utah Osteopathic Medical Association
2011 – Present	American Society of Dermatopathology
2007 – 2014	Association of Military Dermatologists
2004 – Present	American Academy of Dermatology

PROFESSIONAL EXPERIENCE:

Principal Investigator/Sub-Investigator, 2020 – Present
CCT Research, Utah

Dermatologist/Dermatopathologist, 2013 – Present
Springville Dermatology, Springville, UT

Assistant Program Director, 2013 – Present
Aspen Dermatology Residency Program, Utah

Chief of Dermatology, 2007 – 2011
121st Brian Allgood Army Community Hospital, Seoul, Korea

Installation Medical Authority and Chief of Occupational Health Clinic, 2003 – 2004
Umatilla Army Depot, Umatilla, OR

Chief of Primary Care, 2001 – 2003
Rodriguez Army Health Clinic, Fort Buchanan, Puerto Rico

RESEARCH EXPERIENCE:

Metastatic Melanoma • Sebaceous Hyperplasia

CLINICAL TRIAL EXPERIENCE:

A Phase II study of high-dose XXX in patients with Stage III/IV metastatic melanoma.

ACADEMIC RESEARCH EXPERIENCE:

Effect of low dose XXX in treating diffuse sebaceous hyperplasia.

Dermatology research comparing XXX and XXX on collagen and elastin.